Gallery
- Karnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)Wedding pics: Mouni Roy marries Suraj Nambiar in South Indian ceremony73rd Republic Day Parade 2022 - In Pictures
Jyothi Yarraji, who won a silver medal in the 100m hurdles at the Hangzhou Asian Games, wi
- Lione Messi said Retirement not on my mind
- Indian Wells: Alcaraz, Swiatek win titles
- African footballer chased and thrashed away in Kerala; reports
- Hockey India announce core probable group for men's national camp in Bhubaneswar
- Interim Budget: Large number of institutions of higher learning set up, highest ever medal tally in games reflects high confidence level, says FM
Covaxin trials for 2-18 age group to begin in 10-12 days: Govt Last Updated : 18 May 2021 11:54:17 PM IST Clinical trials to test Covaxin vaccine's efficacy in children between two to 18 years of age will begin in 10-12 days, top officials said on Tuesday.
Addressing the Union Health Ministry press conference, NITI Aayog's Member Health, Dr V.K. Paul said: "Covaxin has been approved by the Drugs Controller General of India (DCGI) for Phase 2 and 2 clinical trials in the age group of two to 18 years. I have been told that trials will begin in the next 10-12 days."Covaxin manufacturer Bharat Biotech received the DCGI approval to conduct clinical trials of Covaxin in children on May 11, following the Central Drugs Standard Control Organisation's subject expert committee's recommendation, under certain conditions.Approval of clinical trials of vaccine efficacy among children came amid reports from the US and Canada allowing Pfizer-BioNTech for the 12-15 age groups.The announcement came amid reports that new variants are also affecting children.The clinical trials are expected to be conducted among over 500 participants at various hospitals across the country. AIIMS Director, Dr Randeep Guleria had said that the need of the hour is some quick data and risk-benefit analysis of the vaccine's use in children.Earlier in the day, Congress leader Rahul Gandhi urged the government put in place a vaccine protocol for children.IANS New Delhi For Latest Updates Please-
Join us on
Follow us on
172.31.16.186